Roche's phase 3 CENTERSTONE study shows Xofluza (baloxavir marboxil) significantly reduces influenza transmission in ...

According to the company, the results are the first time an antiviral drug has reduced transmission of a respiratory virus in a global Phase 3 trial.

Data from the CENTERSTONE study shows single-dose Xofluza reduces transmission of influenza from an infected person to ...

Roche (OTCQX:RHHBY) subsidiary Genentech announced on Thursday that Xofluza, an FDA-approved flu antiviral, achieved its ...

According to the findings, the antiviral treatment demonstrated to significantly reduce the transmission of influenza viruses ...

Roche announces phase III CENTERSTONE study of Xofluza significantly reduces the transmission of influenza viruses: Basel Friday, September 20, 2024, 09:00 Hrs [IST] Roche announc ...

Roche today released positive top-line results of the Phase III CENTERSTONE study of Xofluza (baloxavir marboxil), an ...

Xofluza (baloxavir marboxil), an antiviral medication, achieved its primary endpoint in the phase III CENTERSTONE ...

Roche’s antiviral drug Xofluza reduced influenza transmission among household contacts in a large Phase 3 study, the company said Wednesday. Treatment with a single dose of Xofluza within 48 ...

--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results of the Phase III CENTERSTONE study of Xofluza ® (baloxavir ...

Data from the CENTERSTONE study shows single-dose Xofluza reduces transmission of influenza from an infected person to household members – – This is the first time that any antiviral used in ...